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A b s t r a c t  
A sustained release matrix formulation for Ambroxol hydrochloride was designed and developed to 
achieve a 12 h release profile. Using HPMC K15M and Eudragit RSPO as an inert matrix forming 
agent to control the release of Ambroxol hydrochloride. The matrix tablets for these formulations 
were prepared by direct compression and their in-vitro release tests were carried out for a period of 
12 hours using USP dissolution test apparatus (type I- Basket) at       37±0.5°C and 100 rpm speed. 
A 32 full factorial design was used for optimization by taking the concentration of HPMC K15M (X1) 
and Eudragit RSPO (X2) were selected as independent variables, where as initial release at the 2 
hrs (Y1, % drug release), release rate at the 8 hrs (Y2,   % drug release) and the concentration of 
Ambroxol hydrochloride released in 12 hrs (Y3, % drug release) were chosen as dependent 
variables. The optimized formulation F4 follows Hixon Croswell order release kinetics with non-
Fickian diffusion mechanism. From the study, it was concluded that the release of Ambroxol 
hydrochloride can be effectively sustained using combination of HPMC K15M and Eudragit RSPO. 
Keywords: Ambroxol hydrochloride; HPMC K15M; Eudragit RSPO; Direct compression; Factorial 
design 
 
 
 
 
 
Introduction 
Sustained release is most preferred drug delivery system because 
of safety better patience compliance and increased complication 
during the development of new drug entity. Sustained release drug 
delivery systems are designed to achieve a prolonged therapeutic 
effect by continuously releasing medication over an extended 
period of time after the administration of a single dose[1]. Various 
systems such as dissolution controlled release systems, diffusion 
controlled release systems, dissolution and diffusion controlled 
release systems, ion exchange resin- drug complexes, pH 
dependent formulation and osmotic pressure controlled systems. 
Among all this system dissolution controlled system is most 
preferred one. The Dissolution controlled release a system is 
further classified into matrix and reservoir system. Matrix systems 
are important among the sustained release dosage forms because 
of their simplicity, low cost, small influence of physiological 
variables on their release behavior and their suitability for 
manufacture on modern high speed equipment [2,.3] It involves the 
direct compression of blend of drug, retardant material and 
additives to formulate a tablet in which the drug is embedded in a 
matrix of the retardant. The retardant mainly includes both 
hydrophilic and hydrophobic polymers. 
In the present investigation, Ambroxol hydrochloride was selected 
as a model drug. Ambroxol is metabolite of bromohexine with 
similar actions and uses. It is chemically described as Trans-4-[(2-
Amino-3, 5-dibromobenzyl) amino] cyclohexanol and structure is 
shown in Fig. 1 It is an expectoration improver and a mucolytic 
agent in the treatment of acute and chronic disorders characterized 
by the production of excess of thick mucus. It has been 
successfully used for decades in the form of its hydrochloride as a 
secretion releasing expectorant in a variety of respiratory 
disorders.[4-5] Its short biological half life (3-4 hrs) that calls for 
frequent daily dosing (2 to 3 times) and therapeutics use in chronic 
respiratory disease necessitates its formulation into sustained 
release dosage form.[6-8] Therefore, to reduce frequency of dosing 
as well as to increase bioavailability and enable better patient 
compliance, formulating sustained release dosage form was 
necessary.[9-11] 
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Figure 1 Structure of Ambroxol hydrochloride. 
Among different technologies used in controlled drug delivery, 
hydrophilic matrix systems are the most popular because of the 
simplicity of formulation, ease of manufacturing, low cost, FDA ( 
Food and Drug Administration) acceptance, and applicability to 
drugs with wide range of solubility.[12-15] HPMC K15M ( Hydroxy 
Propyl Methyl Cellulose) is an odorless and tasteless, white or 
creamy-white fibrous or granular powder.[16] HPMC, a 
semisynthetic derivative of cellulose, is a swellable and hydrophilic 
polymer  It is very suitable to use as a retardant material in 
controlled release matrix tablets, as it is nontoxic and easy to 
handle.[17] 
Eudragit RSPO is fine, white powders with a slight amine-like odor. 
Eudragit RSPO having 5% of functional quaternary ammonium 
groups. The ammonium groups are present as salts and give rise 
to pH-independent permeability of the polymers. Eudragit RSPO is 
water-insoluble and contain ≥97% of dry polymer.18 The acrylate 
methacrylate polymers have been used in the preparation of matrix 
tablets for oral sustained release, in tablet coating and in the 
microencapsulation of drugs.[19-21] 
The objective of the study is formulation and evaluation of 
sustained release drug delivery of ambroxol hydrochloride using 
computer aided optimization technique i.e. 32 - Full Factorial 
Design. [22-24] The concentration of HPMC K15M (X1) and 
Eudragit RSPO (X2) were selected as independent variables, 
where as drug release at the 2 hrs (Y1), 8 hrs (Y2) and 12 hrs (Y3) 
% drug release of Ambroxol hydrochloride  were chosen as 
dependent variables. 
Materials and Methods 
 Materials 
Ambroxol Hydrochloride drug obtained as gift sample from Shilpa 
Medicare Ltd., India, Hydroxy Ppropyl Methyl Cellulose K15M were 
gifted by Colorcon, India. Eudragit RSPO was gifted by Evonic 
Industries, India, and all other excipients used were of analytical 
grade, and procured from commercial sources. 
Experimental Design 
In the present study, a 32 full factorial design was employed for 
formulation containing two different polymers HPMC K15M (X1) 
and Eudragit RSPO (X2). Optimization is carried out by studying 
effect of independent variables, i.e. Concentration of HPMC K-15M 
(X1) and Eudragit RSPO (X2) on dependent variables. Three 
factorial levels coded for low, medium, and high settings (−1, 0 and 
+1 respectively) were considered for three independent variables. 
The selected dependent variables as initial release at the 2 hrs (Y1, 
% drug release), concentration release rate at the 8 hr (Y2, % drug 
release) and the concentration of Ambroxol hydrochloride released 
in 12 hr (Y3, % drug release)  Table 1 and 2 shows translation of 
coded values to actual values and responses and the preparation 
of formulations and respectively. 2.3 Preparation of Matrix tablets 
The requisite quantity of the polymers was weighed and placed in a 
mortar, which is homogeneously triturated with the help of pestle 
for two minutes. The required quantity of the Ambroxol 
hydrochloride was weighed and uniformly triturated with the 
homogeneous polymer mixture for further 2 minutes. All the 
powders were passed through 18 mesh sieve. The flow property of 
the final blend was found to be satisfactory. The final blend was 
then directly compressed with the 8 mm concave punch using a 
rotatory punch tablet compression machine. 
(M/s.CadmachMachinery,Co.Pvt.Ltd.,India) Compression force 
was kept constant for all formulations. Each tablet contained 75 mg 
Ambroxol hydrochloride. The composition of tablets is given in 
Table 3. In-vitro drug release studies from the prepared matrix 
tablets were conducted for a period of     12 hours using USP 
dissolution test apparatus (type I- Basket) at 37±0.5°C and 100 rpm 
speed. The simulated gastric fluid (pH 1.2) for first 2 hours and 
intestinal fluid (pH 6.8) for next          10 hours without enzymes 
were used as a dissolution medium. Samples (10 ml) were 
withdrawn with replacement at fixed time intervals, the samples 
were then diluted with dissolution medium (when necessary). The 
concentrations of Ambroxol hydrochloride released from the tablet 
formulations were determined at 245 nm using a UV 
spectrophotometer.  
Release Kinetics 
Different mathematical models can be tested to determine which 
best describes the kinetics and mechanism of drug release from 
tablets.25-30 In the present study, data obtained from in-vitro drug 
release studies were plotted in various kinetic models. 
 Zero order Qt = Q0 + K0t                                           
(1)First order   logC= logC0-K1t/2.303                                                                                              
(2)Higuchi Qt = k2t1/2                                   
(3)Hixson_Crowell cuberoot (W01/3= Wt1/3) = kht                                                                              
(4)Korsemeyer_Peppas Qt//Q ∞ = kptn                                                                                                                             
(5)where Qt , Q0 and Q ∞ are the amounts of drug dissolved initially, 
at time t and at time ∞, (in most cases, Q0=0), C0 and C are the 
concentrations of drug initially and at time t, W0 and Wt are the 
amounts of drug in the pharmaceutical dosage form initially and at 
time t, and k0, k1, k2, kh, and kp refer to the rate constants obtained 
from the linear curves of the respective models. 
Statistical analysis and optimization 
Cumulative percents drug release data of 2 hr, 8 hr and 12 hr of all 
model formulations were analysed by Design-Expert software. 
Suitable models for mixture designs consisting of two different 
components include linear, Quadratic models. The best fitting 
mathematical model was selected based on the comparisons of 
several statistical parameters including the coefficient of variation 
(CV), the multiple correlation coefficient (R2); adjusted multiple 
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correlation coefficient (adjusted R2) proved by Design-Expert 
software. From this, indicates how well the model fits the data, and 
for the chosen model it should be small relative to the other models 
under consideration. 
Linear model: Y = b1 X1 + b2 X2  
Quadratic model: Y = b1 X1 + b2 X2 + b1 X1 X2 
To know about relationship between dependent and independent 
variables three dimensional response surface plots were drawn. 
Simultaneously point prediction technique were used to generate 
new formulations with the desired responses. 
2.5 Validation of the experimental design 
To validate the chosen experimental design, the predicted values 
are estimated from         Design-Expert software and experimental 
values of the responses were compared with it, and the predicted 
error (%) calculated by using the following equation (Eq.6), 
% Predicted error = (Predicted value-Experiment value)/ 
Experiment value*100           (6) 
Characterization of the optimized formulation 
Fourier transform infrared spectroscopy (FTIR) 
FTIR study of drug and excipients were carried out to determine 
the interaction between them. The IR spectrum of pure drug, 
HPMC K15M, Eudragit RSPO and Optimized formulation were 
recorded in the stretching frequency range 400-4000 cm-1. The 
samples were prepared by KBr ( Potassium Bromide ) press pellet 
technique. 
Results and discussion 
In-vitro dissolution studies 
The dissolution profiles of all nine formulations given by 
experimental design are shown in Figure 2, and data of mean 
values of various responses i.e Y1, Y2 and Y3 for all the nine 
formulations of experimental design shown in Table 4.  From the 
Figure 1, it was observed that the formulations F1-F3 showed drug 
release rate 93.02%, 92.57% and 90.81% in 12 hrs, F4-F6 showed 
drug release rate of 93.11%, 91.01% and 90.36% in 12 hrs and F7-
F9 showed the drug release rate, 89.27%, 87.26% and 85.58% in 
12 hrs respectively. From the result, it was observed that when 
concentration of Eudragit RSPO increased the drug release rate 
decreases while other is kept constant for three formulations each 
in all F1-F9 formulation. 3.2. Release kinetics 
Data obtained after dissolution profile are fitted to different 
mathematical models (Zero-order, First order, Higuchi, Korsmeyer-
Peppas and Hixson-Crowell) in order to describe the kinetics of 
drug release rate as shown in Table 5. Higher the value of 
regression coefficient (R2) was chosen as criteria for selecting the 
most appropriate model. Korsmeyer-Peppas release exponent (n) 
value of optimized formulation F4 is 0.737 which is greater than 0.5 
indicating non- Fickian transport. 3.3. Data analysis 
Mathematical relationship was generated between the factors 
(independent variables) and responses (dependent variables) 
using the statistical Design-Expert for determining the levels of 
factors, which yield optimum dissolution responses. 
A second order polynomial regression equation that fitted to the 
data is as follows:  
                       Y = b0 + b1X1 + b2X2 +b3 X12 +b4 X22+ b5 X1 X2                                    
(7) 
Where, b0 is the intercept representing the arithmetic mean of all 
the quantitative outcomes of nine experimental runs; b1 to b5 are 
the estimated coefficients from  the observed experimental values 
of Y; X1 and X2 are the coded levels of  factors. The term X1X2 is 
interaction terms show the change in response occurs when two 
factors are simultaneously changed. The Xi2              (where i= 1, 2) 
is quadratic term. The equations of the responses are given below: 
                                  Y1 = 19.60 -1.46 X1 -4.28 X2                                                                      
(8) 
                                  Y2 = 78.50 -7.23X1 -3.94X2 +0.37X1X2 -
2.27X12 -0.87X22                       (9) 
                                  Y3 = 91.14 -2.38X1 -1.44X2 -0.37X1X2 -
1.56X12 +0.26X22                    (10) 
Where, 
           X1= Conc. HPMC K15M,  
           X2 = Conc. Eudragit RSPO 
           Y1 = % drug release at 2 hr 
           Y2 = % drug release at 8 hr 
           Y3 = % drug release at 12 hr 
The equation represents the quantitative effect of factors (X1 and 
X2) upon the responses (Y1, Y2 and Y3). Coefficients with one 
factor represent the effect of that particular factor while the 
coefficients with more than one factor and those with second order 
terms represent the interaction between those factors and the 
quadratic nature of the phenomena, respectively.  
Analysis of variance (ANOVA) was applied for estimating the 
significance of the model, at 5% significance level. A model is 
considered significant if the p-value (significance probability value) 
is less than 0.05. Data from Table 6 contains factor effects of 32 
Full Factorial Design model and associated p-values for the 
responses Y1, Y2 and Y3 are presented. A factor is considered to 
influence the response if the effects significantly differ from zero 
and the p-value is less than 0.05. Positive sign in front of the terms 
indicates synergistic effect while negative sign indicates 
antagonistic effect of the factors, here the response Y1 was 
significantly affected by the antagonistic effect of  linear term of 
HPMC K15M (X1) (p-value 0.0105) and Eudragit RSPO (X2) (p-
value 0.0001), the response Y2 was significantly affected by the 
antagonistic effect of  quadratic term of HPMC K15M (X1) (p-value 
0. 0001) and Eudragit RSPO (X2)        (p-value 0.0001), the 
response Y3 was significantly affected by the antagonistic effect of  
quadratic term of HPMC K15M (X1) (p-value 0. 0001) and Eudragit 
RSPO (X2)                        (p-value 0.0001). 
Bold type figures indicates that significant effects of factors on 
individual responses  
Response surface analysis 
Bankar et al. International Journal of Drug Delivery 4 (3) 375-385 [2012] 
 
PAGE | 378 | 
 
 
 
The 3-dimensional response surface plots were drawn to estimate 
the effect of independent variables on response Y1, Y 2 and Y3 as 
shown in Figure 3,4 and 5 respectively. A mathematical model also 
generated for response Y1 (Eq.8). Simillarly mathematical model  
 
 
Table 1 Translation of Coded Values to Actual Values and Responses 
Variable levels Low (-1) Medium (0) High (+1) 
X1 = Concentration of     HPMC K 15 (mg) 25 30 35 
X2 = Concentration of Eudragit RSPO (mg) 15 20 25 
Responses 
% drug release at the 2 hr (Y1) % drug release at the 8 hr (Y2) % drug release at the 12 hr (Y3) 
 
Table 2 Factorial Design for Preparation of Formulations 
Batch Code Variable levels in Coded form 
X1 X2 
F1 -1 -1 
F2 -1 0 
F3 -1 +1 
F4 0 -1 
F5 0 0 
F6 0 +1 
F7 +1 -1 
F8 +1 0 
F9 +1 +1 
 
Table 3 Composition of Tablets 
Formulation 
(mg/tablet) 
Drug HPMC 
K15M 
Eudragit 
RSPO 
MCC Total Weight 
F1 75 25 15 115 250 
F2 75 25 20 110 250 
F3 75 25 25 105 250 
F4 75 30 15 110 250 
F5 75 30 20 105 250 
F6 75 30 25 100 250 
F7 75 35 15 105 250 
F8 75 35 20 100 250 
F9 75 35 25 95 250 
(Each Formulation contains 5% PVP K-30, 2% Magnesium sterate and 1% Talc) 
 
Table 4 Data of Mean Values of Various Responses i.e Y1, Y2 and Y3 for all the nine Formulations of Experimental Design 
Formulation 
run 
Responses 
Y1 
(% release at 2 hr) 
Y2 
(% released in 8 hr) 
Y3 
( % released in 12 hr) 
F1 25.16±2.86 87.58±3.34 93.02±1.54 
F2 19.23±2.43 82.84±1.34 92.57±3.60 
F3 16.66±4.34 78.26±1.42 90.81±1.36 
F4 27.12±2.43 80.61±4.11 93.11±0.87 
F5 19.99±2.50 78.61±1.44 91.01±4.39 
F6 15.38±3.85 74.11±2.65 90.36±3.45 
F7 20.26±2.83 72.02±2.21 89.27±1.56 
F8 17.70±3.43 69.08±1.11 87.26±2.44 
F9 14.15±1.56 64.17±1.24 85.58±0.45 
Mean, ± S.D., n=3 
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Table 5 Kinetics of drug release based on dissolution profile of ambroxol hydrochloride     tablets 
Formulation Zero order First order Higuchi Hix.-Crow. K-Peppas 
k0 r k1 r r r N R 
F1 18,69 0.897 0.120 0.989 0.953 0.975 0.766 0.968 
F2 12.79 0.915 0.108 0.987 0.963 0.977 0.860 0.966 
F3 8.68 0.929 0.097 0.987 0.968 0.983 0.935 0.967 
F4 15.81 0.954 0.103 0.988 0.988 0.995 0.737 0.989 
F5 7.55 0.968 0.101 0.966 0.979 0.981 0.844 0.982 
F6 2.78 0.977 0.097 0.961 0.966 0.981 0.947 0.982 
F7 8.45 0.973 0.092 0.953 0.961 0.970 0.781 0.967 
F8 2.53 0.970 0.086 0.948 0.948 0.963 0.852 0.955 
F9 1.12 0.973 0.078 0.948 0.942 0.968 0.932 0.967 
k0: Zero order rate constant; k1: First order rate constant; r: Correlation coefficient; n: Diffusion exponent 
 
 
Table 6 Summary of analysis of variance (ANOVA) for the measured response i.e Y1, Y2 and Y3 for amount of drug released at at the 2 hrs, at the 
8 hrs and at the 12 hrs respectively. 
Factor Y1 Y2 Y3 
Factor effect p-value Factor effect p-value Factor effect p-value 
X1 -1.46 0.0105 -7.23 <0.0001 -2.38 <0.0001 
X2 -4.28 <0.0001 -3.94 <0.0001 -1.44 <0.0001 
X1X2   +0.37 0.2374 -0.37 0.0761 
X12   -2.27 0.0003 -1.56 0.0002 
X22   -0.87 0.0394 +0.26 0.2695 
Bold type figures indicates that significant effects of factors on individual responses 
 
Table 7 The Experimental and Predicted Values for Responses Y1, Y2 and Y3 along with Percentage Prediction Error (%PE) observed for 
Optimum Formulation F4 and Random Formulation. 
Response (X1 X2) F4 
(30,15) 
V1 (26,16) V2 (29,18) V3 (31,19) V4 (32,21) V5 
(34,23) 
Y1 Experimental 
Value 
26.12 24.48 22.32 20.65 18.28 15.60 
Predicted Value 25.43 24.62 22.27 20.59 18.38 15.59 
% PE 2.641 -0.571 0.224 0.290 -0.547 0.064 
Y2 Experimental 
Value 
80.61 85.72 81.09 77.82 74.53 68.80 
Predicted Value 81.58 85.67 81.32 77.70 74.44 68.76 
% PE -1.20 0.058 -0.140 0.154 0.120 0.058 
Y3 Experimental 
Value 
93.11 92.99 92.20 91.01 89.75 87.33 
Predicted Value 92.84 93.12 92.14 90.91 89.63 87.28 
% PE 0.28 -0.139 0.065 0.109 0.133 0.057 
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A 
 
B 
 
C 
Figure 2 Dissolution profiles of all nine formulations (A) F1-F3 (B) F4- F6 (C) F7-F9 
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.  
Figure 3 Response Surface Plot Showing the Influence of the HPMC K15M and Eudragit RSPO on the % release at the 2 hr. 
 
Figure 4 Response Surface Plot Showing the Influence of the HPMC K15M and Eudragit RSPO on the % Release at the 8 hr, 
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Figure 5 Response Surface Plot Showing the Influence of the HPMC K15M and Eudragit RSPO on the % Release at the 12 hr 
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(C) 
Figure 6 Correlation between Experimental and Predicted (A) for % drug release at 2 hrs Y1,  (B) % drug release at 8 hrs, Y2 and (C) % drug 
release in 12 hrs, Y3. 
 
Figure 7 FTIR Spectra of Ambroxol hydrochloride, HPMC K15M, Eudragit RSPO and Optimized formulation. 
also generated for response Y2 (Eq.9) and Y3 (Eq.10). 3.5. 
Evaluation and validation of the optimized formulation 
The experiments were carried out according to the composition 
obtained after applying constraints and the optimum formulation 
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was evaluated for the dissolution profile. In order to evaluate the 
reliability of the developed mathematical model, five additional 
checkpoint points were taken estimated by use of generated model 
covering the entire experimental domain.    Table 7 gives the levels 
of variables of optimum formulation and five random checkpoint 
points with their experimental values, predicted values and 
percentage prediction error. The percentage prediction errors 
between the predicted and experimental values for each response 
were calculated and the values found to be within 5%. The 
experimental values were in agreement with the predicted values 
confirming the predictability and validity of the model. 
Table 7 shows the experimental and predicted values for 
responses Y1, Y2 and Y3 along with percentage prediction error 
(%PE) observed for optimum formulation F4 and random 
formulation and Figure 6 shows correlation between observed and 
predicted Y1, Y2 and Y3. Correlation coefficient in both graphs r2 
>0.9 shows goodness of fit of model. Thus, the lower magnitude of 
error as well as significant values of r2 (>0.9) in the current study 
indicate the robustness of the mathematical model and high 
prognostic ability of Response Surface Models. 
The optimized formulation F4 gave % drug release at 2 hrs, 8 hrs 
and 12 hrs values of 27.12%, 80.61% and 93.11% respectively. 
Drug release from the optimized formulation followed Hixson-
Crowell is best fit model for F4 (R2=0.995). Korsmeyer-Peppas 
release exponent (n) value of optimized formulation is 0.737 which 
is greater than 0.5 indicating       non- Fickian transport. 3.6. 
Characterization of the optimized formulation 
FTIR 
From the Figure 7, it was observed that in IR spectra of Ambroxol 
hydrochloride, the peak showed 748.38 cm-1 for out of plane C-H 
deformation, 1064.71 cm-1 for CO equatorial absorption of 
cyclohexane, 1286.52 cm-1 for Ar-NH2,  2791 cm-1 for N-CH2 
streching, 2868.15 cm-1 for C-H stretching and 3396.64 cm-1 for N-
H stretching, In IR spectra of HPMC K15M, the peak showed 
1153.43 cm-1 for saturated ethers, aliphatic ethers, 1426.26 cm-1 
for C-H deformation methyl, propyl, 2835.36 cm-1 for C-H streching 
of alkyl group. In IR spectra of Eudragit RSPO, the peak showed 
1338.60 cm-1 for CO stretching of carboxylic acid, 1446.61cm-1 for 
C-H deformation methyl, propyl, 1732.08 cm-1 for C=O stretching 
of carboxylic acid and 2951.09 cm-1 for salt of quaternary 
ammonium ion. The peaks showed no significant changes in 
material characteristic when Ambroxol hydrochloride used with 
HPMC K-15 and Eudragit RSPO. 
Conclusions 
A 32 randomized full factorial design was used in this study. In this 
design 2 factors were evaluated, each at three levels and 
experimental trials were performed at all nine possible 
combinations. This study revealed that the concentration of HPMC 
K15M and Eudragit RSPO had significantly affect the drug release 
of Ambroxol hydrochloride, it is thus concluded that by adopting a 
systematic formulation approach, an optimum point can be reached 
in shortest time with minimum efforts. 
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